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1. Introduction 
What we are dealing with: Hepatitis C virus (HCV) infection is the commonest blood-borne 
infection, one of the commonest cause of chronic liver disease (CLD) & hepatocellular 
carcinoma (HCC) and one of the commonest reason for liver transplantation (LT) the world 
over.  
What is the meaning of decompensation: Fibrosis is the histopathological hallmark of 
chronic hepatitis causing progressive derangement of normal liver architecture with 
consequent reduction in hepatic synthetic function. CLD is said to be decompensated when 
one or the other complication of CLD has developed - ascites, variceal bleeding (secondary 
to portal hypertension), impaired hepatic synthetic function (hypoalbuminemia), jaundice, 
and/or hepatic encephalopathy. Five years survival rate in decompensated cirrhotics is 
estimated to be 50%.1 
Decompensated cirrhosis is NOT a contraindication to antiviral therapy: 
Decompensated cirrhosis has traditionally been considered a contraindication to 
interferon and ribavirin therapy. Whereas, the same may be true for advanced cirrhosis 
(which is only successfully amenable to LT), there are reports in the literature in which 
antiviral therapy was given successfully in selected cases of early hepatic decompensation 
with an aim to attain sustained viral clearance (SVR), halt disease progression and expect 
potential (though often partial) recovery of hepatic metabolic function. Antiviral therapy 
may also be instituted to prevent hepatitis C recurrence post-transplantation. If HCV is 
not eradicated pre-transplantation, reinfection with HCV occurs in all transplant 
recipients as a rule, with secondary cirrhosis developing in approximately 30% of cases 
within 5 years.2 Pre-transplantation HCV eradication is however associated with less 
likelihood of reinfection and this forms the rationale for treating decompensated cirrhotics 
awaiting LT with antiviral therapy.3 Initiating pre-emptive post-transplantation antiviral 
therapy, and treating established post-transplant HCV hepatitis are other options in LT 
patients. The aim of instituting pre-transplantation antiviral therapy is either to attain a 
sustained virological response (SVR) at transplantation, or an on-treatment HCV RNA 
clearance at transplantation. Mere reduction of viral load should not be the aim because, 
unlike HBV cirrhotics, this has not been shown to decrease the rate &/or severity of post-
transplant HCV recurrence.  
www.intechopen.com
 
Antiviral Drugs – Aspects of Clinical Use and Recent Advances 
 
4 
Thus decompensation per se is not an absolute contraindication for antiviral therapy. 
Although the final SVR rates attained in such patients are lower,21,23 successful antiviral 
therapy is potentially lifesaving which supports the rationale for implementing HCV 
treatment in these patients.  
In this chapter, the pros and cons of antiviral therapy in decompensated liver cirrhosis are 
reviewed with special emphasis on how to avoid antiviral dose reductions/ withdrawals 
secondary to the development of haematologic side effects by using haematopoietic growth 
factors (HGF’s).  
2. Discussion 
2.1 Therapeutic options in decompensated cirrhosis 
In selected cases, HCV-infected decompensated cirrhosis may be treated surgically (i.e. with 
LT) &/or medically (i.e. with antiviral therapy). 
2.2 Surgical option 
LT: How feasible is this option? LT is not a feasible option in the great majority of 
cirrhotics. This is not only because of the limited number of organ donors available at a 
given time, but also because of the age-related cardiovascular, renal, and pulmonary 
derangements that practically make going for this option rather irrational at times. 
Additionally, old age (≥65 years) is generally considered an exclusion criterion for LT.  
2.3 Medical option 
Historical reasons for reluctance to institute medical therapy in decompensated cirrhotics: 
Historically, despite the known theoretical benefits of antiviral therapy (improvement in 
liver histology, partial reversal of established cirrhosis, and prevention of life-threatening 
complications), most decompensated cirrhotics have not been offered antiviral therapy. 
Primarily, this has been due to the concerns regarding the therapeutic efficacy and safety of 
antiviral therapy in such cases. Peginterferon-ribavirin combination therapy is known to 
have limited efficacy in decompensated cirrhotics.4,5 Also, compared to non-cirrhotics, such 
patients are more prone to develop hematologic side effects (neutropenia, thrombocytopenia & 
anemia) with antiviral therapy.6 In fact, patients who already have severe neutropenia or 
thrombocytopenia (neutrophil count <1500/mm3 or platelets count <75,000/mm3) are 
highly prone to develop life-threatening infections after starting antiviral therapy, 
particularly if they have Child–Pugh class C disease.7,8 Also, it is generally thought that age-
related derangements in cardiovascular and pulmonary functions make the cirrhotic 
patients less tolerant to ribavirin-induced hemolytic anemia. Finally, there are concerns that 
decompensation may worsen with antiviral therapy as is the case with decompensated 
chronic hepatitis B cases.9  
Do the reasons for reluctance evidence-based: Current literature reviews shows that 
because of the unstandardized dosage schedules being administered over variable periods 
of time in the past studies, we may have actually under/ overestimated the potential 
benefits and risks of antiviral therapy respectively in decompensated cirrhotics. There are 
now several reports in the literature in which antiviral therapy was relatively well tolerated 
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by decompensated cirrhotics with reasonable rates of attainment of end-of-treatment 
response (ETR) & sustained virological response (SVR):4,7,10,11  
1. In one study,7 39% of the patients receiving low, accelerating regimen of non-pegylated 
interferon plus ribavirin experienced clearance of HCV-RNA, & 21% attained an SVR. 
Results with pegylated interferon are even better. In the first study12 proving the benefits 
of antiviral therapy in cirrhotics with signs of portal hypertension, 51 cirrhotics received 
1mg/kg/wk of pegylated-interferon alpha-2b plus oral ribavirin at a fixed dose of 
800mg/d for 52 wks. By intention-to-treat analysis, SVR was achieved in 21.6% patients. 
As otherwise, patients with genotypes 2 & 3 showed better results (83.3%) than 
genotype 1 cases (13.3%). Although antiviral therapy was stopped in 5 of the patients 
because of neutrophil counts falling below 0.75×103/dL, none of them developed 
superadded infections. The disease deteriorated in only 6% of those who attained SVR 
compared to 38% of the non-responders.  
2. In another study,10 Peg-IFN alpha-2b (1.0 mg/kg/wk) plus standard dose of ribavirin 
were administered to all patients for 24 wks regardless of the genotype. The overall SVR 
rate attained even with this suboptimal dose regimen was 19.7%. Except patients with 
very advanced liver disease (CTP score >10), none experienced life-threatening 
complications. Peg-IFN and ribavirin in the standard dosage (Peg-IFN alpha-2b 
1.5mg/kg & ribavirin 800-1000mg for genotypes 2 and 3, and 1000-1200mg for 
genotypes 1 and 4) for the standard duration of time (48 & 24 wks for genotype 1 & 
non-1, respectively) has also been tried.  
3. In another study,13 35% of end-stage cirrhotics cleared the HCV infection (16% genotype 
1 & 4, and 59% genotype 2 & 3 cases). 60% of all patients tolerated the antiviral therapy 
without any major untoward effects; treatment was discontinued in 19.1% of the 
patients with 4 among those ending up having severe superadded infections.  
4. In yet another study14 a 48 week course was planned for patients who demonstrated 
EVR with a standard regimen of PEG-IFN alfa-2a (135µg, once a week) plus ribavirin 
(1000-1200 mg/day). Results showed 60% patients completing the course with ETR & 
SVR achieved in 45% & 35% cases, respectively.  
5. In a recent study15 aimed to evaluate both the prevention of post-transplantation HCV 
recurrence & the risk of bacterial infections during therapy, 47% patients achieved HCV 
RNA negativity during treatment, 29% were HCV RNA negative at the time of 
transplantation (drop outs n=3, deaths n=4, viral relapse n=2) and 20% achieved an SVR 
post-transplantation. Importantly, none of the patients who achieved SVR pre-
transplantation developed a recurrence post-transplantation.  
3. Evidence-based pharmacotherapy of HCV infection in decompensated 
cirrhotics 
Child–Pugh (sometimes called Child-Turcotte-Pugh [CTP]) scoring – see table 1 - helps 
determine the need and utility of instituting antiviral therapy:   
1. The ideal candidate for antiviral therapy remains a patient with Child–Pugh class A 
disease in whom the risk of drug-induced side effects is almost identical to that of the 
controls. Nonetheless, all cirrhotic patients with a CTP score ≤9 and a decompensated 
event that abated with routine management may be considered for antiviral therapy. 
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2. Whether or not to institute antiviral therapy in Child–Pugh class B patients should be 
individualized on case-to-case basis giving due consideration to factors like genotype (2 
& 3 better than 1) & pre-treatment viral loads (< 800,000 IU/mL better than higher 
loads). In all such cases, antiviral therapy probably should be discontinued after 4 or 12 
weeks if there is no virological response. 
3. Patients with Child–Pugh class C (CTP score ≥10 or MELD score 18 [table 2]) disease are 
not considered appropriate candidates to institute antiviral therapy. 
 
Measure 1 point 2 points 3 points 
Total bilirubin, μmol/l (mg/dl) <34 (<2) 34-50 (2-3) >50 (>3) 
Serum albumin, g/l >35 28-35 <28 
INR <1.7 1.71-2.20 > 2.20 
Ascites None Mild Severe 
Hepatic encephalopathy None Grade I-II  Grade III-IV  
Table 1. Child–Pugh Score 
Points Class One year survival Two year survival 
5-6 A 100% 85% 
7-9 B 81% 57% 
10-15 C 45% 35% 
Table 1.a Interpretation of Child–Pugh Score 
MELD = 3.78[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine 
(mg/dL)] + 6.43 
 
NB: 
1. If the patient has had dialysis at least twice in the past week, then the value for serum 
creatinine used should be 4.0 
2. Any value less than one is given a value of 1 (i.e. if bilirubin is 0.8, a value of 1.0 is 
used). This helps prevent the occurrence of scores below 0 (the natural logarithm of 1 
is 0, and any value below 1 would yield a negative result). 
Ln = natural logarithm 
Table 2. MELD Score (Model For End-Stage Liver Disease) (12 and older): 






Table 2.a Interpretation MELD Score 
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Peginterferon-ribavirin combination therapy (table 3) is now considered the standard drug 
regimen in cases of HCV infection. In peginterferon, an inert polyethylene glycol moiety is 
inserted into the interferon molecule. This causes a decrease in renal clearance and thus an 
increase in the plasma half life (80 hrs) of the peginterferon molecule. Because of the 
prolonged half life, whereas the non-pegylated interferons need to be administered thrice 
weekly, pegylated interferons are administered once weekly. The two formulations of 
peginterferon currently available are peginterferon alpha-2a and 2b. They differ in the size 
and configuration of the polyethylene glycol moiety attached to the interferon molecule. 
Although the two peginterferon formulations have not yet been compared head-to-head in 
the published controlled trails, they are generally believed to be equivalent therapies and 
thus can be used interchangeably.  
 
Drug: Recommended Dosage: 
Peginterferon alfa-2a 
(40 kD)† 

















Genotype 1: Higher weight-adjusted dosage has shown better 
response rates (1000mg if 75kg∆ orally in two divided doses; 
1200mg if >75kg)∞.  
Genotype 2&3: Higher dosage has not been shown in published 
studies to be consistently associated with better response rates. 
Therefore, 800mg/day orally in two divided doses is the 
current dosage of choice regardless of the weight.⌂  
Abbreviations: kD, kilodaltons; μg, micrograms; SQ, subcutaneously; kg, kilograms; mg, milligrams. 
† Peginterferons are therapeutically superior to non-pegylated interferons. 
∂ Peginterferon-ribavirin combination therapy is therapeutically superior to peginterferon monotherapy 
as well as non-pegylated interferon-ribavirin combination therapy.   
∆ More studies are needed to ascertain whether or not the treatment outcomes with 1000mg and 800mg 
ribavirin in patient’s 75kg weight are comparable.  
∞ It is not yet clear whether or not patients heavier than 88 kg will have better outcomes on 1400mg of 
ribavirin than 1200mg.  
⌂ More studies are needed to ascertain that whether or not heavier patients yield better results with 
>800mg of ribavirin dose in genotypes 2 & 3 cases. 
Table 3. Peginterferon-Ribavirin Combination Dosage Regimen: The Current Standard 
After starting antiviral therapy, HCV RNA assay needs to be repeated at specific intervals to 
determine the treatment responses. Depending upon the results of the repeat HCV RNA 
assays, different treatment responses have been defined (table 4).  
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Quantitative HCV RNA assay done at 12 weeks: 
 Comes back to be negative – called early virologic clearance 
(EVC) or aviremic response   
 Shows a decline in the HCV RNA titre (compared with the pre-
treatment assay) of ≥ 2 log – called partial virologic response 
(PVR) or viremic response 
Nonresponders Quantitative HCV RNA assay done at 12 weeks showing either no 
decline in the HCV RNA titre (compared with the pre-treatment 
assay) or a decline of < 2 log 
End of treatment 
response (ETR) 
Qualitative HCV RNA assay done on completion of the recommended 
duration of the treatment course comes back to be negative 
Sustained virologic 
response (SVR)* 
Qualitative HCV RNA assay done 24 weeks after completion of the 
recommended duration of the treatment course comes back to be 
negative 
Relapsers Qualitative HCV RNA assay done on completion of the recommended 
duration of the treatment course was negative (ETR achieved), but 24 
weeks later it becomes positive again (SVR not achieved). . 
*Achievement of SVR is generally considered as the marker of eradication of HCV infection. Almost all 
such patients show EVC or PVR on 12 weeks assay. 
Table 4. Definitions of Treatment Responses 
Positive and negative predictors of therapeutic response:  
1. Positive predictors: As otherwise, attainment of a rapid/ early virological response and 
genotypes 2 & 3 are the most robust predictors of viral clearance with antiviral 
therapy.10,12 Child–Pugh class A and lower pre-transplantation viral loads (< 800,000 
IU/mL) are other positive predictors. 
2. Negative predictors: A reduction in the viral load of ≤2 l log10 between baseline & week 4, 
Child–Pugh class C or MELD >18 have a strong negative predictive value. In the 
absence of a ≥2 log10 reduction in HCV RNA at week 4, probably the best approach to 
reduce the risk of complications is to stop antiviral therapy at this point.  
The exact treatment protocol instituted in a given patient depends upon the genotype. 
Genotypes 2&3 are more responsive to interferon therapy than genotype 1 and therefore 
the recommended duration of antiviral therapy in former is 06 months as compared to 
one year in the latter. Although more data and experience is needed to establish definite 
protocols in genotypes 4, 5 & 6 cases, current evidence suggests treating them as genotype 









HCV RNA Assay: Recommendations according to the PCR results:  
Week 4 qualitative HCV RNA assay:† 
Negative assay (<50IU/mL)  
i.e. a case of RVR 
Shorten the standard treatment course of 24 weeks to 12-
16 weeks. Ribavirin is given at higher weight-adjusted 
dosage in the short courses (1000mg if 75 kg orally in 
two divided doses; 1200mg if >75 kg)‡,∂ 
Positive assay Give treatment for the standard duration of 24 weeks∆ 
(may be 36-48 weeks) 
Week 24 qualitative HCV RNA assay: 
Negative assay i.e. a case of 
ETR 
Successful therapy. Needs a repeat qualitative HCV RNA 
assay at week 48 (24 weeks after ETR) to establish SVR 
Positive assay Treatment failed 
Week 48 qualitative HCV RNA assay: 
Negative assay i.e. a case of 
SVR 
HCV infection eradicated 
Positive assay i.e. a case of 
relapse 
Previously treated with non-pegylated interferon:  
Treat with peginterferon and ribavirin. If EVR is not 
achieved at week 12, stop the treatment 
Previously treated with pegylated interferon: 
Retreatment is not indicated even if a different type of 
peginterferon is administered. Consensus interferon has 
shown to improve responses in such cases, but it is too 
premature to recommend it.  
 
† The newly recommended week 4 qualitative HCV RNA assay helps modify the duration of the 
therapy based on viral kinetics. On one hand, this approach helps maximize the SVR rates and on the 
other hand, limits the toxicities and cost associated with the extended treatment courses. Achievement 
of RVR means that we can consider shortening the treatment course. 
‡ With the shortened treatment courses in subjects who show RVR, SVR rates of 80-100% have been 
reported in genotype 2 cases and 77-85% in genotype 3 cases.  
∂ In case of relapse, retreatment with the standard 24 weeks course is recommended. 
∆ SVR rates achieved in this subgroup are poor, particularly in genotype 3 cases – 41-58%. In genotype 2 
cases, the results are relatively better - 50-89%. Because of the poor SVR rates, prolonged therapy (>24 
weeks) may be considered in this subgroup, although more evidence is needed at this time for a definite 
recommendation.  
 
Table 5. Summary of Current Standards in the Management of Genotypes 2&3 Cases: 
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HCV RNA Assay: Recommendations as per the PCR results:  
Week 4 qualitative HCV RNA assay: 
Negative assay (<50IU/mL) 
i.e. a case of RVR 
Predictors of poor response absent:† 
Shorten the treatment duration to a total of 24 weeks‡,∂ 
Predictors of poor response present: 
Give treatment for the standard duration of 48 weeks 
Positive assay Continue treatment and repeat HCV RNA at 12 weeks 
Week 12 qualitative HCV RNA assay: 
Negative assay i.e. a case of 
EVC 
Continue treatment for a total of 48 weeks 
HCV RNA fall by ≥ 2 logs i.e. 
a case of PVR 
Continue treatment & repeat qualitative HCV RNA at 24 
weeks. 
HCV RNA fall by < 2 logs i.e. 
a case of non-responder 
Stop treatment 
Week 24 qualitative HCV RNA assay 
(only done in cases which show PVR at week 12 assay):  
Negative assay (this 
subgroup is called ‘slow 
responders’) 
Continue treatment for a total of 48-72 weeks. 72 weeks 
therapy has generally shown superior results as 
compared to 48 weeks therapy in slow responders.  
Positive assay Stop treatment as probability of attaining SVR is 
negligible 
Week 48 qualitative HCV RNA assay: 
Negative assay i.e. a case of 
ETR 
Successful therapy. Needs a repeat qualitative HCV 
RNA assay at week 72 (24 weeks after ETR) to establish 
SVR 
Positive assay Treatment failed  
Week 72 qualitative HCV RNA assay: 
Negative assay i.e. a case of 
SVR 
HCV infection got eradicated 
Positive assay i.e. a case of 
relapse 
Previously treated with non-pegylated interferon:  
Treat with peginterferon and ribavirin. If EVR is not 
achieved at week 12, stop the treatment 
Previously treated with pegylated interferon: 
Retreatment is not indicated even if a different type of 
peginterferon is administered. Consensus interferon has 
shown to improve responses in such cases, but it is too 
premature to recommend it.  
† Old age (>50yrs); male gender; African American race; obesity; alcoholism; HIV confection or 
immunosuppression; more-than-portal fibrosis on liver biopsy (Metavir ≥2 or Ishak ≥ 3); a pretreatment 
viral load of >800,000IU/mL. 
‡ SVR rates of 80-89% can be achieved in this subgroup.  
∂ In case of relapse, retreatment with the standard 48 weeks course is recommended. 
Table 6. Summary of Current Standards in the Management of Genotype 1 Cases 
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Monitoring the antiviral therapy not only involves asking repeat HCV RNA assays at 
specific intervals to determine therapeutic response, but also a battery of other blood tests to 




CBC at weeks 1, 2, 4, 6, 8 and then monthly 
Week 4: Qualitative HCV RNA assay at week 4 in both genotype 1 and 2&3 cases to 
assess for RVR 
Every 
month: 
Pregnancy assay in a sexually-active female of child bearing age 




LFTs, INR, albumin, creatinine, urinalysis, glucose and TSH 
Week 24:  Qualitative HCV RNA assay at week 24 in only those genotype 1 cases 
who attained EVR at week 12 
 Qualitative HCV RNA assay at week 24 in genotype 2&3 cases to 
determine ETR 
Week 48  Qualitative HCV RNA assay at week 48 in genotype 2&3 cases to determine 
SVR 
 Qualitative HCV RNA assay at week 48 in genotype 1 cases to determine 
ETR 
Week 72  Qualitative HCV RNA assay at week 72 in genotype 1 cases to determine 
SVR 
Table 7. Monitoring of Anti-viral Therapy 
4. Pharmacotherapy of side effects 
As a general rule, decompensated cirrhotics are more prone to develop drug-induced side-
effects compared to patients with compensated disease. Important side effects in 
decompensated cirrhotics include:16 
1. Drug-induced hematological side effects: neutropenia (50–60%), thrombocytopenia (30–
50%), hemolytic anemia (30–50%). 
2. Superadded infections: spontaneous bacterial peritonitis (SBP), spontaneous 
bacteraemia/ septicaemia/ septic shock (due to Gram-negative bacilli) etc (4–13%). 
3. Worsening of hepatic decompensation with therapy (11–20%). 
4.1 Drug-induced hematological side effects 
4.1.1 Ribavirin-induced hemolytic anemia 
The minimum effective dose of ribavirin appears to be 10.6 mg/kg/day. In case hemolytic 
anemia develops, it is recommended to first reduce the dose of ribavirin to the minimum 
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effective level. If no or little improvement in hemoglobin (Hb) level occurs, initiating 
concomitant erythropoietin (EPO) therapy may be considered.17,18  
 
Possible indications: 1. Fall in Hb level by >4 g/dL.  
2. Hb levels of <8g/dL.  
3. Development of symptoms and signs attributable to anemia 
(palpitations, dyspnea, easy fatigability, pallor).21,22 
Dosage regimens: 1. 20,000-40,000IU/week given in three divided doses 
subcutaneously (max. 60,000IU/week) with an aim to achieve 
& maintain Hb level of ≥10g/dL (return to the pretreatment 
level is NOT the aim).23  
2. Another study suggested starting EPO therapy at a lower dose 
of 4,000IU subcutaneously thrice weekly (12,000IU/week) and 
then increasing the dose depending upon the response.24 
Table 8. Erythropoietin (EPO) therapy 
Monitoring EPO therapy: The first evidence of response to the thrice weekly EPO 
administration is an increase in the reticulocyte count within 10 days.25 Since erythroid 
progenitors take several days to mature, a clinically significant increase in hematocrit is 
usually not observed in less than 2 weeks and may require up to 6 weeks in some 
patients.26 If the rate of rise of hemoglobin is greater than 1 g/dL over 2 weeks, it 
generally warrants decreasing EPO dose. This is because a greater than 1 g/dL rise in any 
2 weeks during the course of the therapy has been associated with an increased risk of 
thromboembolic phenomenon, predisposing to myocardial infarction, stoke and even 
death.27 Also, according to manufacturer’s recommendations, a Hb level of greater than 
12g/dL should not be aimed, the reason being potentially increased risk of 
thromboembolic phenomenon.28 Once adequate Hb level (≥10g/dL) is achieved, ribavirin 
dose can be increased to the optimum level.20 Once started, adjunct EPO therapy may be 
required until the end of the treatment. In one study,24 the median duration of EPO 
treatment was 24 weeks (range 6–39).  
4.1.2 Interferon-induced neutropenia/ thrombocytopenia 
The minimum effective dose of pegylated interferon appears to be 1 μg/kg/wk. It is 
recommended to reduce IFN dose to the minimum effective level if neutrophil count falls to 
<0.5x109/L, and discontinue it if it falls to <0.3x109/L.17 Regarding platelet count, IFN dose 
should be reduced to the minimum effective level if platelet count falls to <30x109/L, and 
discontinued if it falls to <20x109/L.17 If no or little improvement in neutrophil/ platelet 
counts occur, initiating concomitant granulocyte-colony-stimulating-factor (G-CSF) or 
granulocyte-monocyte-colony-stimulating-factor (GM-CSF) therapy may be considered19,20  
with an aim to avoid using the suboptimal drug doses.  
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Possible indications: 1. Neutrophil count <0.5x109/L. 
2. Platelet count <30x109/L 
Dosage regimens: 3. 30MU subcutaneously once weekly and then adjusting the 
dose as per the response/ requirement. 
 
Table 9. Granulocyte-colony-stimulating-factor (G-CSF) therapy 
Monitoring G-CSF therapy: Complete blood counts should be requested twice or thrice 
weekly and response to therapy judged. Once adequate neutrophil count is achieved, IFN 
dose can be increased to the optimum level.21 Once started, adjunct G-CSF therapy may be 
required till the end of the treatment. In one study,24 the median duration of G-CSF therapy 
was 20 weeks (range 9–45). 
4.2 Pharmacotherapy of superadded infections 
Norfloxacin prophylaxis has been shown to reduce the incidence of superadded 
infections.15,16 In cases of established nosocomial SBP (often caused by bacteria resistant to 
3rd-generation cephalosporins and/or amoxicillin-clavulanic acid), broad-spectrum 
antibiotics like carbapenems or glycopeptides should be prescribed.  
Although it is not yet clear how much survival benefit antiviral therapy confers, a 
standardized mortality rate analysis in one study reported a lower liver-related mortality 
among cirrhotics with SVR (0.6: CI: 0.0-3.1) compared to untreated patients.29 In post-liver 
transplant cases, avoidance of allograft failure due to recurrence of HCV infection has also 
been reported in the literature although it needs further studies and validation.30 
5. Conclusion 
One thing that has become increasingly clear from the existing trials data is that cirrhotic 
patients who are treated with antiviral therapy and who achieve SVR are less likely to 
develop liver-related complications as compared to the non-responders. Despite the many 
encouraging studies on this subject, data on the long-term disease progression, avoidance of 
transplantation, and most importantly, improvement of life expectancy is however still 
sparse. Although liver functions have clearly been shown to improve with antiviral therapy 
(as indicated by significant reductions in CTP and MELD scores), the same are more likely 
to deteriorate within a few years in patients with advanced cirrhosis thus explaining the 
need to accumulate data on the possible survival benefit conferred by antiviral therapy in 
cirrhotic patients.  
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